Medicus Pharma Ltd. filed a current report on November 19, 2026, disclosing that the company received a conditional compliance notice from Nasdaq on November 18, 2026, indicating that a prior listing deficiency related to Market Value of Listed Securities had been lifted after the company demonstrated compliance with an alternative shareholders' equity requirement.
Key Highlights
- Deficiency lifted: Nasdaq notified Medicus Pharma that the Market Value of Listed Securities deficiency under Nasdaq Listing Rule 5550(b)(2) had been lifted.
- Alternative standard met: The company demonstrated compliance with the alternative minimum shareholders' equity requirement of $2.5 million under Nasdaq Listing Rule 5550(b)(1).
- Compliance is conditional: Nasdaq's notice stated that compliance is conditioned upon the company evidencing continued compliance with the minimum shareholders' equity requirement in its next periodic report for the period ending December 31, 2026.
- Delisting risk remains: According to the filing, if the company does not evidence compliance in that report, "the Company may be subject to delisting from Nasdaq."
- Original deficiency notice: The Market Value of Listed Securities had been below $35 million for 30 consecutive business days as of May 20, 2026, triggering the initial noncompliance notice.
- Securities listed: The company's common shares (NASDAQ:MDCX) and warrants (NASDAQ:MDCXW) are both registered on the Nasdaq Capital Market.
Medicus Pharma's Path to Conditional Nasdaq Compliance in November 2026
According to the filing, Medicus Pharma Ltd., an Ontario-incorporated pharmaceutical company with principal executive offices in Conshohocken, Pennsylvania, had been under a Nasdaq listing review since May 20, 2026. On that date, the Listing Qualifications Department of Nasdaq notified the company that its Market Value of Listed Securities had fallen below $35 million for the previous 30 consecutive business days, placing it out of compliance with Nasdaq Listing Rule 5550(b)(2). The company was given until November 16, 2026 to regain compliance or satisfy an alternative continued listing standard.
The filing disclosed that on November 18, 2026, Medicus Pharma received the Conditional Compliance Notice from Nasdaq. The notice stated that the deficiency had been lifted because the company demonstrated compliance with the alternative minimum shareholders' equity requirement of $2.5 million set forth in Nasdaq Listing Rule 5550(b)(1), giving effect to transactions described in a separate current report the company filed with the SEC on November 16, 2026. The company also issued a press release on November 19, 2026, regarding these matters, furnished as Exhibit 99.1.
The filing noted that the conditional compliance status carries an ongoing obligation. The company must evidence continued compliance with the minimum shareholders' equity requirement in its next periodic report covering the period ending December 31, 2026. The filing stated: "There can be no assurance that the Company will be able to maintain compliance with the minimum shareholders' equity requirement, that Nasdaq will determine that the Company has satisfied the condition set forth in the Conditional Compliance Notice or that the Company will be able to maintain compliance with Nasdaq's other continued listing requirements in the future." The filing also noted that the forward-looking statements it contains are the company's own and are subject to its cautionary language and the risk factors detailed in its regulatory filings.
What Was Disclosed
Medicus Pharma Ltd. disclosed receipt of a conditional Nasdaq compliance notice on November 18, 2026, lifting a Market Value of Listed Securities deficiency after the company satisfied an alternative $2.5 million shareholders' equity requirement, with continued listing contingent on the December 31, 2026 periodic report.




Please wait processing your request...